Sentences with phrase «oligodendrocyte progenitor cells»

Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitor Cell Transplants Remyelinate and Restore Locomotion After Spinal Cord Injury.

Surgeons injected millions of oligodendrocyte progenitor cells grown from hESCs into the injury site through a fine needle, hoping the cells would stimulate nerve growth and re-sheathe nerves damaged through the injury.

Human Embryonic Stem Cell - Derived Oligodendrocyte Progenitor Cell Transplants Improve Recovery After Cervical Spinal Cord Injury.

Sep 14, 2016 ISCoS meeting 2016 Initial Clinical Trials of hESC - Derived Oligodendrocyte Progenitor Cells in Subacute Spinal Cord Injury

Cerebral white matter injury (WMI) persistently disrupts myelin regeneration by oligodendrocyte progenitor cells (OPCs).

Although lost mature oligodendrocytes can principally be replaced by resident oligodendrocyte progenitor cells (OPCs) this does not happen sufficiently enough in the human spinal cord after injury.

«Introduction of a novel system for in vitro analyses of zebrafish oligodendrocyte progenitor cells.»

AST - OPC1 is comprised of oligodendrocyte progenitor cells manufactured from our pluripotent embryonic stem cell platform.

Asterias has banks of these embryonic stem cells, derived from this cell line, which the company can multiply to make cells as needed and, in turn, convert them into oligodendrocyte progenitor cells for use in clinical trial evaluation in patients.

Starting with transplants of human oligodendrocytes in the late 1980s [40], and more recently with populations of human oligodendrocyte progenitor cells isolated from the developing or adult CNS, or from human embryonic stem cells, it has been possible to generate extensive myelination upon transplantation into spinal cord injury or into congenital mouse models of hypomyelination [41]--[48].

Ten people will receive injections into the injury site of hESC - derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin.

«There are currently no therapies which successfully reverse the damage seen in the more than 12,000 individuals who suffer a spinal cord injury each year in the United States alone,» says Dr. Richard G. Fessler, professor of neurological surgery at Rush University Medical Center and principal investigator for the Phase 1 clinical trial involving AST - OPC1 (oligodendrocyte progenitor cells).

This type of stem cell, called an oligodendrocyte progenitor cell, is found in the brain and spinal cord.

«Oligodendrocyte Progenitor Cells,» or OPCs, are progenitor cells — similar to stem cells — that have the capacity to differentiate during tissue repair.

Most of these trials involve stem cell - derived neural progenitor cells, which can turn into several different types of brain or spinal cord cells, or oligodendrocyte progenitor cells, which create the myelin sheaths that insulate and protect nerve cells.

Most of these trials involve stem cell — derived neural progenitor cells, which can turn into several different types of brain or spinal cord cells, or oligodendrocyte progenitor cells, which create the myelin sheaths that insulate and protect nerve cells.

At the International Society for Stem Cell Research 2017 Annual Meeting (June 14 - 17, 2017; Boston, USA), Asterias Biotherapeutics, Inc (CA, USA) will present new 9 - month efficacy and safety data from their ongoing SCiStar Phase I / IIa trial of human embryonic stem cell - derived oligodendrocyte progenitor cells.

Oligodendrocyte Progenitor Cells Derived from Human Embryonic Stem Cells Express Neurotrophic Factors.

Immunological properties of human embryonic stem cell - derived oligodendrocyte progenitor cells.

AST - OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1 / 2a dose escalation clinical trial in spinal cord injury.

GRNOPC1, hESC - derived oligodendrocyte progenitor cells, have been assessed by Geron for treatment of spinal cord injury.

AST - OPC1, an oligodendrocyte progenitor cell population derived from human embryonic stem cells, has been shown in preclinical testing in animals and in vitro to have three potentially reparative functions that address the complex pathologies observed in demyelination disorders, such as spinal cord injuries, and multiple neurodegenerative diseases, including multiple sclerosis and white matter stroke.